ACKSONVILLE, Florida, September 6, 2016, TPIV, /PRNewswire/ — TapImmune, Inc. (TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer & metastatic disease, today issued a shareholder update regarding significant recent financial, clinical and regulatory milestones achieved, as well as an outlook on future catalysts. Dear Shareholders: We believe recent events have been transformative for TapImmune. We believe we are now funded to execute on the 4 PhaseRead more
- How to Choose the Right Cryptocurrency to Invest in 2018
- mCig’s Subsidiary, Grow Contractors Inc., Announces it has Secured an Exclusive Management Contract in Sacramento, CA, Paving the Way to an Expanded Presence in the State
- MoneyTV with Donald Baillargeon, 4/20
- Alternate Health Launches First Complete Ethereum Blockchain EMR / EHR
- NutraFuels, Inc. (NTFU) Provides 2017 Year End Financials Revenues Increase 694.6%
SMALL CAP MARKET NEWS
We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.
LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!
Stock Investors · Accredited Investors · Hedge Fund InvestorsLearn More